4//SEC Filing
Ghai Jyotsna 4
Accession 0000950170-25-027105
CIK 0001850906other
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 8:10 PM ET
Size
13.4 KB
Accession
0000950170-25-027105
Insider Transaction Report
Form 4
Ghai Jyotsna
Chief Operating Officer
Transactions
- Disposition to Issuer
Restricted Stock Unit
2025-02-21$20.00/sh−3,000$60,000→ 0 total→ Common Stock (3,000 underlying) - Disposition to Issuer
Common Stock
2025-02-21−3,283→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21$9.20/sh−13,333$122,664→ 0 totalExercise: $10.80Exp: 2033-03-15→ Common Stock (13,333 underlying) - Disposition to Issuer
Restricted Stock Unit
2025-02-21$20.00/sh−4,583$91,660→ 0 total→ Common Stock (4,583 underlying)
Footnotes (6)
- [F1]The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").
- [F2]As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
- [F3]Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.
- [F4]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F5]The RSU was subject to a service-based vesting condition over a four-year period in 16 equal quarterly installments measured from February 9, 2024. As of the Effective Time, the vesting of the RSU was accelerated in full. Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in the preceding sentence, each vested RSU was canceled and automatically converted into the right to receive, without interest and less any applicable tax withholdings, $20.00 in cash.
- [F6]The RSU was subject to a service-based vesting condition over a four-year period in 16 equal quarterly installments measured from March 15, 2023. As of the Effective Time, the vesting of the RSU was accelerated in full. Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in the preceding sentence, each vested RSU was canceled and automatically converted into the right to receive, without interest and less any applicable tax withholdings, $20.00 in cash.
Documents
Issuer
Singular Genomics Systems, Inc.
CIK 0001850906
Entity typeother
Related Parties
1- filerCIK 0001999779
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 8:10 PM ET
- Size
- 13.4 KB